2-pyrrolidone

1-Ethyl-2-pyrrolidone ,with CAS No. 2687-91-4, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. 1-Ethyl-2-pyrrolidone provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

2-Pyrrolidinone is a characteristic compound present in cabbage. It is the lactam cyclization product of γ -aminobutyric acid (GABA) and has anti-cancer properties.

(R)-5-Oxopyrrolidine-2-carboxylic acid (D-Pyroglutamic acid) is a cyclic derivative of glutamic acid, physiologically present in mammalian tissues. It releases GABA from the cerebral cortex and exhibits anti-anxiety effects in a simple approach-avoidance conflict situation in rats. In clinical pharmacology experiments, it significantly shortens the plasma half-life of ethanol during acute intoxication.

N-Methylpyrrolidone (1-Methyl-2-pyrrolidinone) is a five-membered cyclic amide and a widely used industrial organic polar solvent in the manufacture of adhesives, paints, fuels, and pharmaceuticals.

4E1rcat 17d features a core structure of (E)-3-(2-furanmethylmethylene)-2-pyrrolidone, and its analog 4E1rcat blocked the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays with IC50 values of 1.1 μM and 1.7 μM, respectively.

ATG5-PPI Inhibitor 17e has a core structure of (E)-3-(2-furanmethylene)-2-pyrrolidone. In in vitro binding assays, this inhibitor blocks the interactions between ATG5 and ATG16L1, as well as between ATG5 and TECAIR, with an IC50 value of >33 μM for both interactions.

ATG5-PPI Inhibitor 17h features a core structure of (E)-3-(2-furfurylmethylene)-2-pyrrolidone, and it blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays with an IC₅₀ of >33 μM for both.

ATG5-TECAIR Inhibitor 17i has a core structure of (E)-3-(2-furylmethylene)-2-pyrrolidone and blocks the interaction between ATG5 and TECAIR in an in vitro binding assay, with an IC50 > 33 μM.

4E1rcat analogue 1 has a core structure of (E)-3-(2-furanmethylmethylene)-2-pyrrolidone, and its analog 4E1rcat blocked the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays with IC50 values of 1.1 μM and 1.7 μM, respectively.

4E1rcat analogue 4 has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. Its analogue 4E1rcat blocked the interaction between ATG5-ATG16L1 and ATG5-TECAIR in the in vitro binding assay, with IC50 values of 1.1 μM and 1.7 μM respectively.

ATG5-PPI Inhibitor 27e has a core structure of (E)-3-(2-furfurylmethylene)-2-pyrrolidone, and it blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays with IC₅₀ values of >33 μM and 17.26 μM, respectively.

The 4E1rcat analogue 6 has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. Its analogue 4E1rcat blocked the interaction between ATG5-ATG16L1 and ATG5-TECAIR in the in vitro binding assay, with IC50 values of 1.1 μM and 1.7 μM respectively.

4E1rcat analogue 7 possesses an (E)-3-(2-furylmethylene)-2-pyrrolidone core structure. Its analog 4E1rcat blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays, with IC50 values of 1.1 μM and 1.7 μM, respectively.

ATG5-PPI Inhibitor 27g has an (E)-3-(2-furylmethylene)-2-pyrrolidone core structure and blocks the interactions between ATG5‑ATG16L1 and ATG5‑TECAIR in in vitro binding assays, with IC50 values of 25 μM and 16 μM, respectively.

4E1rcat analogue 9 has an (E)-3-(2-furylmethylene)-2-pyrrolidone core structure. Its analog 4E1rcat blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays, with IC50 values of 1.1 μM and 1.7 μM, respectively.

ATG5-PPI Inhibitor 27a has a core structure of (E)-3-(2-furylmethylene)-2-pyrrolidone and blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays, with IC50 values of 2.29 μM and 3.68 μM, respectively.

ATG5-TECAIR Inhibitor 12c features a core structure of (E)-3-(2-furfurylmethylene)-2-pyrrolidone and blocks the interaction between ATG5 and TECAIR in in vitro binding assays with an IC₅₀ of 31.24 μM.

ATG5-TECAIR Inhibitor 12e contains an (E)-3-(2-furylmethylene)-2-pyrrolidone core structure and blocks the interaction between ATG5 and TECAIR in an in vitro binding assay, with an IC50 value of 20.79 μM.

ATG5-PPI Inhibitor 12f has a core structure of (E)-3-(2-furfurylmethylene)-2-pyrrolidone and blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays, with IC50 values of >33 μM and 19.16 μM, respectively.